Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States
One in 13 adults used GLP-1 RAs. GLP-1 RA users had greater overall, third-party, and out-of-pocket expenditures. These findings underscore the growing economic impact of GLP-1 RA use and highlight the importance of developing strategies that balance the proven clinical advantages of GLP-1 RAs against their financial burden.
Authors
- Usha Sambamoorthi (ORCID: https://orcid.org/0000-0001-8311-1360)
- Rafia S. Rasu (ORCID: https://orcid.org/0000-0002-6485-9629)
- Bo Zhou (ORCID: https://orcid.org/0000-0003-4213-726X)
- Nsima Akpan
Institutions
- University of North Texas (US)
- University of North Texas Health Science Center (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-12-24
- DOI
- https://doi.org/10.18553/jmcp.2026.32.1.14
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00